0010 - Statement - Condensed Consolidated Statement of Earnings
link:presentationLink
link:calculationLink
link:definitionLink
0030 - Statement - Condensed Consolidated Statement of Cash Flows
link:presentationLink
link:calculationLink
link:definitionLink
0040 - Statement - Condensed Consolidated Balance Sheet
link:presentationLink
link:calculationLink
link:definitionLink
0045 - Statement - Condensed Consolidated Balance Sheet (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
0000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
1010 - Disclosure - Basis of Presentation
link:presentationLink
link:calculationLink
link:definitionLink
1020 - Disclosure - Supplemental Financial Information
link:presentationLink
link:calculationLink
link:definitionLink
1030 - Disclosure - Taxes on Earnings
link:presentationLink
link:calculationLink
link:definitionLink
1040 - Disclosure - Litigation and Environmental Matters
link:presentationLink
link:calculationLink
link:definitionLink
1050 - Disclosure - Post-Employment Benefits
link:presentationLink
link:calculationLink
link:definitionLink
8020 - Disclosure - Comprehensive Income, net of tax
link:presentationLink
link:calculationLink
link:definitionLink
1070 - Disclosure - Incentive Stock Programs
link:presentationLink
link:calculationLink
link:definitionLink
1080 - Disclosure - Business and Technology Acquisitions
link:presentationLink
link:calculationLink
link:definitionLink
1090 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures
link:presentationLink
link:calculationLink
link:definitionLink
1100 - Disclosure - Goodwill and Intangible Assets
link:presentationLink
link:calculationLink
link:definitionLink
1110 - Disclosure - Restructuring Plans
link:presentationLink
link:calculationLink
link:definitionLink
8030 - Disclosure - Subsequent Event - Litigation Settlement
link:presentationLink
link:calculationLink
link:definitionLink
3020 - Disclosure - Supplemental Financial Information (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
8120 - Disclosure - Supplemental Financial Information (Details 2)
link:presentationLink
link:calculationLink
link:definitionLink
4020 - Disclosure - Supplemental Financial Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
8320 - Disclosure - Supplemental Financial Information (Details 3)
link:presentationLink
link:calculationLink
link:definitionLink
8330 - Disclosure - Conclusion of TAP Pharmaceutical Products Inc. Joint Venture (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
8340 - Disclosure - Conclusion of TAP Pharmaceutical Products Inc. Joint Venture (Details)
link:presentationLink
link:calculationLink
link:definitionLink
8210 - Disclosure - Taxes on Earnings (Details)
link:presentationLink
link:calculationLink
link:definitionLink
3050 - Disclosure - Post-Employment Benefits (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
4050 - Disclosure - Post-Employment Benefits (Details)
link:presentationLink
link:calculationLink
link:definitionLink
4040 - Disclosure - Litigation and Environmental Matters (Details)
link:presentationLink
link:calculationLink
link:definitionLink
8110 - Disclosure - Comprehensive Income, net of tax (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
3060 - Disclosure - Segment Information (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
4060 - Disclosure - Segment Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
3070 - Disclosure - Incentive Stock Programs (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
4070 - Disclosure - Incentive Stock Programs (Details)
link:presentationLink
link:calculationLink
link:definitionLink
3090 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
4090 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Details)
link:presentationLink
link:calculationLink
link:definitionLink
4091 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Details 2)
link:presentationLink
link:calculationLink
link:definitionLink
4092 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Details 3)
link:presentationLink
link:calculationLink
link:definitionLink
4100 - Disclosure - Goodwill and Intangible Assets (Details)
link:presentationLink
link:calculationLink
link:definitionLink
3110 - Disclosure - Restructuring Plans (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
4110 - Disclosure - Restructuring Plans (Details)
link:presentationLink
link:calculationLink
link:definitionLink
8240 - Disclosure - Business and Technology Acquisitions (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
4080 - Disclosure - Business and Technology Acquisitions (Details)
link:presentationLink
link:calculationLink
link:definitionLink
8310 - Disclosure - Goodwill and Intangible Assets (Details 2)
link:presentationLink
link:calculationLink
link:definitionLink
8000 - Statement - Consolidated Statement of Shareholders' Investment
link:presentationLink
link:calculationLink
link:definitionLink
8040 - Disclosure - Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
8050 - Disclosure - Debt and Lines of Credit
link:presentationLink
link:calculationLink
link:definitionLink
8060 - Disclosure - Conclusion of TAP Pharmaceutical Products Inc. Joint Venture and Sale of Abbott's Spine Business
link:presentationLink
link:calculationLink
link:definitionLink
8070 - Disclosure - Quarterly Results (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
1060 - Disclosure - Segment Information
link:presentationLink
link:calculationLink
link:definitionLink
8010 - Statement - Consolidated Statement of Shareholders' Investment (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
8250 - Disclosure - Quarterly Results (Unaudited) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
8260 - Disclosure - Quarterly Results (Unaudited) (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
8290 - Disclosure - Debt and Lines of Credit (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
8300 - Disclosure - Debt and Lines of Credit (Details)
link:presentationLink
link:calculationLink
link:definitionLink
8220 - Disclosure - Post-Employment Benefits (Details 2)
link:presentationLink
link:calculationLink
link:definitionLink
8160 - Disclosure - Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
8170 - Disclosure - Summary of Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
8190 - Disclosure - Summary of Significant Accounting Policies (Details 2)
link:presentationLink
link:calculationLink
link:definitionLink
8130 - Disclosure - Conclusion of TAP Pharmaceutical Products Inc. Joint Venture and Sale of Abbott's Spine Business (Details)
link:presentationLink
link:calculationLink
link:definitionLink
4030 - Disclosure - Taxes on Earnings (Details)
link:presentationLink
link:calculationLink
link:definitionLink
8200 - Disclosure - Taxes on Earnings (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
4061 - Disclosure - Segment Information (Details 2)
link:presentationLink
link:calculationLink
link:definitionLink
8230 - Disclosure - Segment Information (Details 3)
link:presentationLink
link:calculationLink
link:definitionLink
8080 - Disclosure - Subsequent Event
link:presentationLink
link:calculationLink
link:definitionLink
8140 - Disclosure - Subsequent Event (Details)
link:presentationLink
link:calculationLink
link:definitionLink
8100 - Disclosure - SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
link:presentationLink
link:calculationLink
link:definitionLink
8270 - Disclosure - Schedule II Valuation and Qualifying Accounts (Table)
link:presentationLink
link:calculationLink
link:definitionLink
8280 - Disclosure - Schedule II Valuation and Qualifying Accounts (Details)
link:presentationLink
link:calculationLink
link:definitionLink
8150 - Disclosure - Schedule II Valuation and Qualifying Accounts (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
4093 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Details 4)
link:presentationLink
link:calculationLink
link:definitionLink
8090 - Disclosure - Separation into Two Publicly Traded Companies
link:presentationLink
link:calculationLink
link:definitionLink
4120 - Disclosure - Separation of Abbott's Proprietary Pharmaceuticals Business (Details)
link:presentationLink
link:calculationLink
link:definitionLink
1120 - Disclosure - Separation of Abbott's Proprietary Pharmaceuticals Business
link:presentationLink
link:calculationLink
link:definitionLink
0020 - Statement - Condensed Consolidated Statement of Comprehensive Income
link:presentationLink
link:calculationLink
link:definitionLink
0025 - Statement - Condensed Consolidated Statement of Comprehensive Income (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
8180 - Disclosure - Summary of Significant Accounting Policies (Details)
link:presentationLink
link:calculationLink
link:definitionLink
4010 - Disclosure - Basis of Presentation (Details)
link:presentationLink
link:calculationLink
link:definitionLink